Firering Strategic Minerals: From explorer to producer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.00
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 1.00 (2.532%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 40.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

Tue, 05th Mar 2024 17:09

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

STV Group PLC - Glasgow-based broadcaster - Revenue grows 22% to GBP168.4 million in 2023 from GBP137.8 million a year prior. Total advertising revenue drops 12% to GBP97.3 million from GBP110.0 million. Adjusted pretax profit was GBP9.5 million for the year, down from GBP24.1 million in 2022. STV's dividend was flat for the year at 11.3p per share, after a final dividend of 7.4p. STV has secured GBP87 million in future revenue as at March, GBP30 million a head of the same time a year ago, and the company is encouraged by the "resilience" shown by the advertising market in the year so far. Chief Executive Officer Simon Pitts says: "Our overall financial performance was impacted by weak linear advertising and cost inflation, as expected and related to the challenging UK macro environment, although the start of 2024 has been more encouraging."

----------

Avacta Group PLC- Wetherby, England-based life sciences company specialising in oncology treatments - Set to issue 10.9 million new shares at a price of 50p each following its February retail offer. This remains subject to shareholder approval at the company's annual general meeting on March 18. The REX offer received total applications in excess of the GBP6.8 million limit. The company decided to limit the offer to existing Avacta retail shareholders, and expects a total of GBP5.4 million to be raised from the offer. The company says the proceeds will be used to support the continued clinical development of AVA6000, the company's signature treatment capable of targeting a chemotherapy to the tumour while sparing healthy tissue.

----------

Argo Blockchain PLC - London-based cryptocurrency miner - Enters into agreement for sale of Mirabel, Quebec data centre for a total consideration of USD6.1 million. The proceeds from the sale will be used to repay the facility's outstanding mortgage in full, and the remainder used to pay debts owned to Galaxy Digital Holdings Ltd, an asset manager and trade advisor specialising in digital assets. As of February 29, the Galaxy debt stands at USD14.0 million. The company is in the process of moving mining machines out of the Mirabel facility, and expects the transaction to close by the end of March.

----------

Harland & Wolff Group Holdings PLC - London-based fabrication company, which serves the maritime and offshore industries - Says it has been awarded preferred bidder status for the Falkland Islands Port Replacement Project by the Falkland Islands Government. H&W believes this contract could generate total revenues between GBP100 and GBP120 million over a two-year period, with works on the project expected to commence this year.

----------

Oxford BioMedica PLC - Oxfordshire, England-based gene and cell-therapy company - Updates annual guidance, expecting 2024 revenue of around GBP126 million to GBP134 million. Guidance for the 2023 full-year remains unchanged, with group revenue expected to be around GBP90 million. The group is expecting a loss before interest, tax, depreciation and amortisation for 2023, but is targeting break-even operating Ebitda by the end of 2024.

----------

By Hugh Cameron, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
23 Aug 2018 14:20

Lombard Odier Asset Management Lowers Holding In Avacta (ALLISS)

LONDON (Alliance News) - Avacta Group PLC on Thursday said Lombard Odier Asset Management Europe Ltd reduced its holding in the biotechnology company.In a transaction on Tuesday, Lombard to

Read more
30 Jul 2018 18:17

UPDATE: Avacta Raises GBP12 Million To Fund New Drug Development (ALLISS)

LONDON (Alliance News) - Biotherapeutics firm Avacta Group PLC late Monday said it raised GBP11.6 million before expenses to help fund new drug development partnerships.Early on Monday, to

Read more
30 Jul 2018 12:48

Avacta Sets GBP11.4 Million Share Offer To Fund New Drug Development (ALLISS)

LONDON (Alliance News) - Biotherapeutics firm Avacta Group PLC on Monday said it plans to raise GBP11.4 million in a share placing and subscription to help fund new drug development is to place at

Read more
24 Jul 2018 11:26

Avacta enters into 'groundbreaking' drug development partnership

(Sharecast News) - Avacta Group's shares surged after the biotherapeutics developer agreed a co-development partnership with Bach BioSciences, a company commercialising the research of William Bachovchin, professor of developmental, chemical and molecular Biology at Tufts University School of Medicine in Boston.

Read more
11 Jun 2018 10:48

Avacta Appoints Ex-Immunocore Boss Eliot Forster As Chairman

LONDON (Alliance News) - Biotechnology firm Avacta Group PLC said Monday it appointed ex-Immunocore Ltd boss Eliot Forster as its non-executive chairman.Forster served as Immunocore CEO in

Read more
29 Mar 2018 13:58

Avacta Says Non-Executive Director Michael Albin To Stand Down Friday

LONDON (Alliance News) - Avacta Group PLC, a healthcare products company that specialises in Affimer products that bind molecules together, said Thursday that non-executive be

Read more
13 Mar 2018 14:26

DIRECTOR DEALINGS: Avacta Chief Executive Officer Smith Buys Shares

LONDON (Alliance News) - Avacta Group PLC said its Chief Executive Officer Alastair Smith bought shares in the biotechnology company in transaction on Tuesday.Smith at

Read more
20 Jan 2017 10:17

Avacta expects licensing deal for therapeutics product in 2017, order book swells

(ShareCast News) - Life science firm Avacta expects to have its first licensing deal for Affirmer, its biotherapeutics product, this year as its order book swelled. In an update for the six months ended 31 January, the the company said that its order book for Affimer grew 70% year-on-year, which alo

Read more
7 Nov 2016 09:41

Avacta Adds Cancer Stem Cell Specialist Evan To Scientific Board

Read more
2 Nov 2016 15:59

Avacta announces collaboration with Memorial Sloan Kettering Cancer Center

(ShareCast News) - Avacta Group announced a research collaboration with Memorial Sloan Kettering Cancer Center on Wednesday, to evaluate the use of the company's 'Affimer' technology in novel CAR-T cell-based immunotherapy. The AIM-traded firm said CAR-T immunotherapy is a form of cancer treatment i

Read more
17 Oct 2016 10:54

Avacta Group narrows loss as revenues rise

(ShareCast News) - Biotherapeutic, research and diagnostic reagent developer Avacta Group announced its preliminary results for the year to 31 July on Monday, with revenues and losses in line with market expectations. The AIM-traded company said it was well funded at period end, with cash balances o

Read more
22 Sep 2016 15:56

Avacta reveals positive results from Affirmer studies

(ShareCast News) - Affimer biotherapeutics and research reagents developer Avacta Group announced positive results from the first preclinical in-vivo studies of its therapeutic Affimer molecules on Thursday. The AIM-traded company said the results meaningfully de-risk the development of the technolo

Read more
22 Sep 2016 07:57

Avacta Reports Good First Results From Affimer Pre-Clinical Trials

Read more
10 Aug 2016 09:28

Avacta collaboration programme gets £3.8m grant

(ShareCast News) - A collaboration programme between AIM-listed Avacta and Leeds University has been awarded a £3.8m grant by the Medical Research Council. The biotherapeutics and research reagents developer said the grant was to develop novel, rapid diagnostic tools incorporating Affimer reagents,

Read more
10 Aug 2016 07:43

Avacta-Leeds University Partnership Gets GBP3.8 Million Grant

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.